Report Detail
Global Vunakizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4706237 |
- 09 June, 2026 |
- Global |
- 74 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Vunakizumab market size was valued at US$ 25.72 million in 2025 and is forecast to a readjusted size of US$ 185 million by 2032 with a CAGR of 8.6% during review period.
Vunakizumab is a humanized anti‑IL‑17A monoclonal antibody independently developed by Hengrui Medicine. It can specifically bind to Interleukin‑17A (IL‑17A), block its interaction with receptors, inhibit inflammatory signaling pathways, and reduce inflammation in the skin, joints and other tissues. It is mainly used for the treatment of psoriasis, ankylosing spondylitis, psoriatic arthritis and other autoimmune diseases, characterized by high affinity, long half‑life, long dosing interval and good safety.In 2025, global vunakizumab production reached approximately 1.2 million vials.
Vunakizumab is a Class 1 domestic innovative drug independently developed by Hengrui Medicine and one of the first anti-IL-17A monoclonal antibodies approved in China. Since its launch, it has rapidly become an important participant in the therapeutic market for autoimmune diseases. With the advantages of high affinity, low immunogenicity, rapid onset and convenient administration, the drug has broken the long-term monopoly of imported IL-17A inhibitors and provided a domestic alternative for patients with psoriasis, ankylosing spondylitis and other diseases. Driven by three core factors, namely medical insurance coverage, expanded indications and optimized pricing, its market penetration has been continuously improved, making it a core growth product in the field of domestic autoimmunity. In terms of competitive landscape, vunakizumab and selicilizumab from Chuangxiang Jintai constitute the first echelon of domestic IL-17A inhibitors, forming a competition pattern of "import-dominated, domestic catching-up" with imported products from Novartis, Eli Lilly and other companies. In the future, relying on Hengrui's commercialization capacity, medical insurance volume expansion effect and potential indication expansion (such as psoriatic arthritis and rheumatoid arthritis), vunakizumab is expected to further expand its market share and promote domestic substitution and price penetration in the domestic autoimmune disease treatment market.
This report is a detailed and comprehensive analysis for global Vunakizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Vunakizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Vunakizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Vunakizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Vunakizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Vunakizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Vunakizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Suzhou Shengdiya Biopharmaceutical, Jiangsu Hengrui Medicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Vunakizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
120 mg / 1 ml
240 mg / 2 ml
Market segment by Production Technology
Innovator
Generic
Market segment by Antibody Type
Monoclonal Antibody
Polyclonal Antibody
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Moderate to Severe Plaque Psoriasis
Ankylosing Spondylitis
Others
Major players covered
Suzhou Shengdiya Biopharmaceutical
Jiangsu Hengrui Medicine
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vunakizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vunakizumab, with price, sales quantity, revenue, and global market share of Vunakizumab from 2021 to 2026.
Chapter 3, the Vunakizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vunakizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Vunakizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vunakizumab.
Chapter 14 and 15, to describe Vunakizumab sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Vunakizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 120 mg / 1 ml
- 1.3.3 240 mg / 2 ml
- 1.4 Market Analysis by Production Technology
- 1.4.1 Overview: Global Vunakizumab Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
- 1.4.2 Innovator
- 1.4.3 Generic
- 1.5 Market Analysis by Antibody Type
- 1.5.1 Overview: Global Vunakizumab Consumption Value by Antibody Type: 2021 Versus 2025 Versus 2032
- 1.5.2 Monoclonal Antibody
- 1.5.3 Polyclonal Antibody
- 1.6 Market Analysis by Sales Channels
- 1.6.1 Overview: Global Vunakizumab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospital
- 1.6.3 Retail
- 1.6.4 Online
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Vunakizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 Moderate to Severe Plaque Psoriasis
- 1.7.3 Ankylosing Spondylitis
- 1.7.4 Others
- 1.8 Global Vunakizumab Market Size & Forecast
- 1.8.1 Global Vunakizumab Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Vunakizumab Sales Quantity (2021-2032)
- 1.8.3 Global Vunakizumab Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Suzhou Shengdiya Biopharmaceutical
- 2.1.1 Suzhou Shengdiya Biopharmaceutical Details
- 2.1.2 Suzhou Shengdiya Biopharmaceutical Major Business
- 2.1.3 Suzhou Shengdiya Biopharmaceutical Vunakizumab Product and Services
- 2.1.4 Suzhou Shengdiya Biopharmaceutical Vunakizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Suzhou Shengdiya Biopharmaceutical Recent Developments/Updates
- 2.2 Jiangsu Hengrui Medicine
- 2.2.1 Jiangsu Hengrui Medicine Details
- 2.2.2 Jiangsu Hengrui Medicine Major Business
- 2.2.3 Jiangsu Hengrui Medicine Vunakizumab Product and Services
- 2.2.4 Jiangsu Hengrui Medicine Vunakizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Jiangsu Hengrui Medicine Recent Developments/Updates
3 Competitive Environment: Vunakizumab by Manufacturer
- 3.1 Global Vunakizumab Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Vunakizumab Revenue by Manufacturer (2021-2026)
- 3.3 Global Vunakizumab Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Vunakizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Vunakizumab Manufacturer Market Share in 2025
- 3.4.3 Top 6 Vunakizumab Manufacturer Market Share in 2025
- 3.5 Vunakizumab Market: Overall Company Footprint Analysis
- 3.5.1 Vunakizumab Market: Region Footprint
- 3.5.2 Vunakizumab Market: Company Product Type Footprint
- 3.5.3 Vunakizumab Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Vunakizumab Market Size by Region
- 4.1.1 Global Vunakizumab Sales Quantity by Region (2021-2032)
- 4.1.2 Global Vunakizumab Consumption Value by Region (2021-2032)
- 4.1.3 Global Vunakizumab Average Price by Region (2021-2032)
- 4.2 North America Vunakizumab Consumption Value (2021-2032)
- 4.3 Europe Vunakizumab Consumption Value (2021-2032)
- 4.4 Asia-Pacific Vunakizumab Consumption Value (2021-2032)
- 4.5 South America Vunakizumab Consumption Value (2021-2032)
- 4.6 Middle East & Africa Vunakizumab Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Vunakizumab Sales Quantity by Type (2021-2032)
- 5.2 Global Vunakizumab Consumption Value by Type (2021-2032)
- 5.3 Global Vunakizumab Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Vunakizumab Sales Quantity by Application (2021-2032)
- 6.2 Global Vunakizumab Consumption Value by Application (2021-2032)
- 6.3 Global Vunakizumab Average Price by Application (2021-2032)
7 North America
- 7.1 North America Vunakizumab Sales Quantity by Type (2021-2032)
- 7.2 North America Vunakizumab Sales Quantity by Application (2021-2032)
- 7.3 North America Vunakizumab Market Size by Country
- 7.3.1 North America Vunakizumab Sales Quantity by Country (2021-2032)
- 7.3.2 North America Vunakizumab Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Vunakizumab Sales Quantity by Type (2021-2032)
- 8.2 Europe Vunakizumab Sales Quantity by Application (2021-2032)
- 8.3 Europe Vunakizumab Market Size by Country
- 8.3.1 Europe Vunakizumab Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Vunakizumab Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Vunakizumab Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Vunakizumab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Vunakizumab Market Size by Region
- 9.3.1 Asia-Pacific Vunakizumab Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Vunakizumab Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Vunakizumab Sales Quantity by Type (2021-2032)
- 10.2 South America Vunakizumab Sales Quantity by Application (2021-2032)
- 10.3 South America Vunakizumab Market Size by Country
- 10.3.1 South America Vunakizumab Sales Quantity by Country (2021-2032)
- 10.3.2 South America Vunakizumab Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Vunakizumab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Vunakizumab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Vunakizumab Market Size by Country
- 11.3.1 Middle East & Africa Vunakizumab Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Vunakizumab Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Vunakizumab Market Drivers
- 12.2 Vunakizumab Market Restraints
- 12.3 Vunakizumab Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Vunakizumab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Vunakizumab
- 13.3 Vunakizumab Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Vunakizumab Typical Distributors
- 14.3 Vunakizumab Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Vunakizumab. Industry analysis & Market Report on Vunakizumab is a syndicated market report, published as Global Vunakizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Vunakizumab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
